News

A new collaborative group involving academic and industry researchers and patient advocacy groups conducted a large-scale study to find serum biomarkers for Duchenne muscular dystrophy (DMD). The study was recently published in the journal Proceedings of the National Academy of Sciences (PNAS) and is entitled “…

The Muscular Dystrophy Association (MDA) has begun another season of its well known summer camp, marking its 60th year in operation. The MDA summer camp aims to support families by hosting thousands of children struggling against muscular dystrophy and similar conditions that seriously limit their mobility and muscular strength. The summer camp assists kids in helping them…

Managing muscular dystrophy (MD) is not an easy task, and it depends not only medical intervention, but also on methods to improve patients’ quality of life. “Supporting People & Pets through Opportunity and Training” (SPPOT) is a community interest company focused on that purpose, helping to train…

Germany’s Federal Joint Committee (G-BA) published a positive Benefit Assessment for Translarna (ataluren), including an evaluation of the benefits of the drug in treating nonsense mutation Duchenne Muscular Dystrophy (nmDMD) in ambulatory patients older than five years. The therapy, which was developed by PTC Therapeutics, was rated “three” — or minor additional benefits…

Sarepta Therapeutics, Inc. , a biopharmaceutical company focused on developing innovative RNA-based therapeutics, has announced a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) pertaining to its lead product candidate eteplirsen — a Duchenne muscular dystrophy (DMD) treatment. Sarepta and the agency are agreed…

Jordan McLinn is turning 6 years old and his mom has a single birthday wish: the possibility of watching him grow up and have the opportunity of becoming the firefighter that he dreams of becoming. Jordan suffers from a deadly type of muscular dystrophy, Duchenne, which will begin to immobilize him within a few years and dramatically…

BioMarin Pharmaceutical Inc. announced the presentation of data regarding disease progression in patients with Duchenne Muscular dystrophy (DMD) at the 67th American Academy of Neurology (AAN) 2015 Annual Meeting in Washington, D.C., April 18-25. The presentation was entitled “Evaluating the Progression of Physical Impairment, Activity Limitation, and Quality…

The Indoor Waterpark and opening weekend at Camelback Lodge in Pennsylvania played a major role in making this year’s 28th annual MDA Ride for Life event a major success. The event, which was held between May 1 to 3, raised over $1.1 million to help families that are affected by muscular dystrophy and…

Catabasis Pharmaceuticals, a company focused on clinical-stage drug development that is supported by a pharmacology technology platform pathway, recently announced that Joanne Donovan, Chief Medical Officer, was invited by Parent Project Muscular Dystrophy (PPMD) to present the latest updates on the upcoming MoveDMD trial. MoveDMD is a Phase ½ clinical trial for …

La Jolla Pharmaceutical Company, a drug development company working on therapies that address life-threatening diseases such as Duchenne muscular dystrophy, recently announced it has entered into an exclusive agreement to acquire the Indiana University Research and Technology Center’s (IURTC) intellectual property rights that cover the derivatives of their next-generation experimental…